ChronoScale Corporation Common Stock - CHRN Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $6.00
  • Forecasted Upside: -49.79%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$11.95
▲ +0.15 (1.27%)

This chart shows the closing price for CHRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ChronoScale Corporation Common Stock Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHRN

Analyst Price Target is $6.00
▼ -49.79% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for ChronoScale Corporation Common Stock in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a -49.79% upside from the last price of $11.95.

This chart shows the closing price for CHRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 2 contributing investment analysts is to reduce stock in ChronoScale Corporation Common Stock. This rating has held steady since February 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/12/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/10/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/11/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/9/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/5/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/6/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/6/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/27/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/31/2025HC WainwrightDowngradeBuy ➝ Neutral
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/18/2025HC WainwrightSet TargetBuy ➝ Buy$4.00 ➝ $6.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
5/6/2025HC WainwrightLower TargetBuy ➝ Buy$135.00 ➝ $60.00
3/4/2025Lake Street CapitalLower TargetBuy ➝ Buy$30.00 ➝ $15.00
3/4/2025HC WainwrightReiterated RatingBuy ➝ Buy$135.00 ➝ $135.00
1/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$135.00 ➝ $135.00
10/29/2024Lake Street CapitalLower TargetBuy ➝ Buy$37.50 ➝ $30.00
10/29/2024HC WainwrightLower TargetBuy ➝ Buy$150.00 ➝ $135.00
7/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$150.00 ➝ $150.00
6/24/2024Lake Street CapitalInitiated CoverageBuy$37.50
4/30/2024HC WainwrightBoost TargetBuy ➝ Buy$138.75 ➝ $150.00
3/5/2024HC WainwrightLower TargetBuy ➝ Buy$150.00 ➝ $138.75
1/22/2024HC WainwrightBoost TargetBuy ➝ Buy$135.00 ➝ $150.00
4/28/2023500.comReiterated RatingReiterates
3/30/2023HC WainwrightReiterated RatingBuy$135.00
7/29/2022HC WainwrightLower TargetBuy$165.00 ➝ $135.00
11/3/2021HC WainwrightReiterated RatingBuy
7/30/2021HC WainwrightReiterated RatingBuy$165.00
(Data available from 5/7/2021 forward)

News Sentiment Rating

-0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2025
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2025
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2025
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/7/2026
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/8/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/7/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/7/2026

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ChronoScale Corporation Common Stock logo
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $11.95
Low: $10.56
High: $11.80

50 Day Range

MA: $10.63
Low: $8.02
High: $12.71

52 Week Range

Now: $11.95
Low: $2.73
High: $13.50

Volume

97,466 shs

Average Volume

56,049 shs

Market Capitalization

$42.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of ChronoScale Corporation Common Stock?

The following Wall Street sell-side analysts have issued reports on ChronoScale Corporation Common Stock in the last twelve months: HC Wainwright, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for CHRN.

What is the current price target for ChronoScale Corporation Common Stock?

0 Wall Street analysts have set twelve-month price targets for ChronoScale Corporation Common Stock in the last year. Their average twelve-month price target is $6.00, suggesting a possible downside of 49.8%. HC Wainwright has the highest price target set, predicting CHRN will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for ChronoScale Corporation Common Stock in the next year.
View the latest price targets for CHRN.

What is the current consensus analyst rating for ChronoScale Corporation Common Stock?

ChronoScale Corporation Common Stock currently has 1 sell rating and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for CHRN.

What other companies compete with ChronoScale Corporation Common Stock?

How do I contact ChronoScale Corporation Common Stock's investor relations team?

ChronoScale Corporation Common Stock's physical mailing address is 101 GLACIER POINT, SAN RAFAEL, CA, 94901. The company's listed phone number is 510-984-1761 and its investor relations email address is [email protected]. The official website for ChronoScale Corporation Common Stock is www.eksobionics.com. Learn More about contacing ChronoScale Corporation Common Stock investor relations.